Chemical: Drug
dimenhydrinate

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Generic Names
  • Diphenhydramine Theoclate
  • Diphenhydrinate
Trade Names
  • Amosyt
  • Anautine
  • Andramine
  • Antemin
  • Aviomarin
  • Chloranautine
  • Diamarin
  • Dimate
  • Dimenest
  • Dimentabs
  • Dramalen
  • Dramamin
  • Dramarin
  • Dramilin
  • Dramyl
  • Dromyl
  • Eldodram
  • Gravinol
  • Gravol
  • Hydrinate
  • Menhydrinate
  • Neo-Navigan
  • Novamine
  • Permital
  • Reise-Engletten
  • Supremal
  • Teodramin
  • Travelin
  • Travelmin
  • Troversin
  • Vomex A
  • Xamamina
Brand Mixture Names

PharmGKB Accession Id

PA449338

Type(s):

Drug

Description

Dimenhydrinate (Dramamine, Gravol and Vertirosan) is an over-the-counter drug used to prevent motion sickness. It is closely related to diphenhydramine HCl, or Benadryl. It is primarily a H1-antagonist, but also possesses an antimuscarinic effect.

Source: Drug Bank

Indication

Used for treating vertigo, motion sickness, and nausea associated with pregnancy.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The mechanism by which some antihistamines exert their antiemetic, anti-motion sickness, and antivertigo effects is not precisely known but may be related to their central anticholinergic actions. They diminish vestibular stimulation and depress labyrinthine function. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Dimenhydrinate is a competitive antagonist at the histamine H1 receptor, which is widely distributed in the human brain. Dimenhydrinate's anti-emetic effect is probably due to H1 antagonism in the vestibular system in the brain.

Source: Drug Bank

Pharmacology

Dimenhydrinate is an antiemetics drug combination that contains diphenhydramine and theophylline. It is not effective in the treatment of nausea associated with cancer chemotherapy. Dimenhydrinate directly inhibits the stimulation of certain nerves in the brain and inner ear to suppress nausea, vomiting, dizziness, and vertigo. Diphenhydramine and dimenhydinate both reduce vestibular neuronal excitation due to angular or linear acceleration motions.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic (cytochrome P-450 system).

Source: Drug Bank

Protein Binding

98 to 99%.

Source: Drug Bank

Absorption

Well absorbed after oral administration.

Source: Drug Bank

Half-Life

1 to 4 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include delerium, hallucinations, and excitment. Patients may be violent and confused.

Source: Drug Bank

Chemical Properties

Chemical Formula

C24H28ClN5O3

Source: Drug Bank

Isomeric SMILES

CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2

Source: Drug Bank

CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

Source: Drug Bank

Canonical SMILES

CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+]

Source: Drug Bank

Average Molecular Weight

469.964

Source: Drug Bank

Monoisotopic Molecular Weight

469.188067494

Source: Drug Bank

SMILES

CN1C2=C([N-]C(Cl)=N2)C(=O)N(C)C1=O.C[NH+](C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C17H21NO.C7H7ClN4O2/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h3-12,17H,13-14H2,1-2H3;1-2H3,(H,9,10,13)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2E1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP3A4

Drug Targets

Gene Description
HRH1 (source: Drug Bank )

Drug Interactions

Interaction Description
dimenhydrinate - donepezil Possible antagonism of action (source: Drug Bank )
dimenhydrinate - donepezil Possible antagonism of action (source: Drug Bank )
dimenhydrinate - galantamine Possible antagonism of action (source: Drug Bank )
dimenhydrinate - galantamine Possible antagonism of action (source: Drug Bank )
dimenhydrinate - rivastigmine Possible antagonism of action (source: Drug Bank )
dimenhydrinate - rivastigmine Possible antagonism of action (source: Drug Bank )
donepezil - dimenhydrinate Possible antagonism of action (source: Drug Bank )
donepezil - dimenhydrinate Possible antagonism of action (source: Drug Bank )
galantamine - dimenhydrinate Possible antagonism of action (source: Drug Bank )
galantamine - dimenhydrinate Possible antagonism of action (source: Drug Bank )
tacrine - dimenhydrinate The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank )
tacrine - dimenhydrinate The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents. (source: Drug Bank )
trimethobenzamide - dimenhydrinate Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )
triprolidine - dimenhydrinate Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
triprolidine - dimenhydrinate Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects. (source: Drug Bank )
trospium - dimenhydrinate Trospium and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects. (source: Drug Bank )

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to dimenhydrinate: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complicated pain management in a CYP450 2D6 poor metabolizer. Pain practice : the official journal of World Institute of Pain. 2007. Foster Adriana, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0409-0468-05
DrugBank:
DB00985
ChEBI:
4604
KEGG Drug:
D00520
PubChem Compound:
441281
PubChem Substance:
46504881
7847586
Drugs Product Database (DPD):
2241532
ChemSpider:
390044
Therapeutic Targets Database:
DAP000333
FDA Drug Label at DailyMed:
fd0b42d6-6733-4525-6283-715ee5a466a9

Clinical Trials

These are trials that mention dimenhydrinate and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.